|
Case
|
Age/sex
|
Time (months)
|
Scr (μmol/L)
|
UTP (g/24 h)
|
MIg
|
Cryo
|
C3 (g/L)
|
C4 (g/L)
|
ER-IO
|
Treatment
|
F. time (months)
|
Renal outcome
|
CLL/SLL
|
|---|
|
1
|
67/M
|
2
|
118
|
10.35
|
IgMλ
|
Trace
|
0.57↓
|
0.12
|
LN
|
CYC, CsA
|
56
|
Not recovery
|
Stable
|
|
2
|
66/M
|
0
|
616
|
0.80
|
Negative
|
Trace
|
0.63
|
0.26
|
LN, BM
|
Supportive
|
52
|
ESRD (never recovered)
|
Stable
|
|
3
|
58/F
|
0
|
95
|
1.15
|
IgGκ
|
Negative
|
0.92
|
0.21
|
BM
|
COP, Rituximab Ibrutinib
|
32
|
Completely recovery
|
Improved
|
|
4
|
58/F
|
0
|
174
|
0.48
|
IgMκ
|
Negative
|
0.48↓
|
0.05↓
|
LN,BM
|
RFC
|
31
|
Completely recovery
|
Stable
|
|
5
|
66/F
|
60
|
570
|
0.87
|
Negative
|
NA
|
0.72
|
0.34
|
LN, Spleen BM
|
CHOP, Ibrutinib
|
15
|
Partial recovery
|
Stable
|
|
6
|
62/M
|
36
|
118
|
4.27
|
IgGκ
|
IgGκ
|
0.57↓
|
0.09↓
|
LN,BM
|
COP, Ibrutinib
|
8
|
Completely recovery
|
Stable
|
|
7
|
68/F
|
18
|
456
|
2.17
|
Negative
|
NA
|
0.81
|
0.16
|
LN,
|
Prednisone
|
6
|
Partial recovery
|
Improved
|
|
8
|
59/F
|
0
|
377
|
0.59
|
IgMκ
|
Type II
|
0.46↓
|
0.02↓
|
LN,BM
|
PE for TMA
|
33
|
Partial recovery
|
Progressed
|
|
9
|
73/M
|
3
|
161
|
1.44
|
Negative
|
Negative
|
0.76
|
0.20
|
BM
|
Supportive
|
2
|
Not recovery
|
Stable
|
|
10
|
67/M
|
0
|
221
|
12.8
|
IgMκ
|
IgMκ
|
0.244↓
|
0.06↓
|
LN,BM
|
Ibrutinib
|
1
|
Partial recovery
|
Stable
|
- Notes: Time: time from diagnosis of CLL/SLL to renal biopsy; Scr: serum creatinine at renal biopsy
- Abbreviations: UTP urine total protein, MIg monoclonal immunoglobulin determined by serum/urine immunofixation electrophoresis; Cryo cryoglobulinemia, ER-IO extra-renal involved organs, F.time follow up time, LN lymph node, BM bone marrow, CYC cyclophosphamide, CsA cyclosporine, ESRD end stage renal disease, COP cyclophosphamide, vincristine, and prednisone, RFC rituximab, fludarabine and cyclophosphamide, CHOP cyclophosphamide, doxorubicin, vincristine and prednisone, PE plasma exchange, TMA thrombotic microangiopathy
